LifeStance Health Group, Inc.
NASDAQ:LFSTMedical - Care Facilities
+$0.17 today
- Market cap
- $5.24B
- Beta
- 1.19
- P/E (TTM)
- 146.6
- EPS (TTM)
- $0.06
Volume 6.60M
Average 3.91M
LFST Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
LifeStance Health Group, Inc.NASDAQ: LFST
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $14.25M rose 1.7% year over year, ahead of the -5.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.
Context
- Depreciation & amortization amounted to 3.8% of revenue in FY2025, down 1.8 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1.7% holds above the trailing-twelve-month pace of -5.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 54.75M USD
- Year-over-year change
- -22.8%
- 4-year CAGR
- +0.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.75M | -22.8% |
| FY2024 | 2024-12-31 | 70.95M | -11.8% |
| FY2023 | 2023-12-31 | 80.44M | +16.2% |
| FY2022 | 2022-12-31 | 69.2M | +27.8% |
| FY2021 | 2021-12-31 | 54.14M | — |
Depreciation & Amortization vs competitors
How LFST compares with its peers on the latest reported figures
- LFST's LTM Jun 2026 depreciation & amortization of $54.56M is the 5th highest of the 7 companies compared; the peer median is $113.97M.
- Its year-over-year change of -5.2% is the 6th highest of 7, against a peer median of +8.8%.
- Depreciation & amortization amounts to 3.4% of revenue for LFST, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $641.16M | +7.5% | +2.1% | 3.5% | |
| LTM Sep 2026 | $201.74M | +10.2% | +17.1% | 5.9% | |
| LTM Sep 2026 | $158.41M | -11.8% | -7.0% | 1.0% | |
| LTM Sep 2026 | $69.52M | +63.7% | +93.9% | 2.4% | |
| LTM Jun 2026 | $54.56M | -5.2% | -7.5% | 3.4% | |
| LTM Jun 2026 | $12.06M | +48.7% | +29.4% | 0.5% | |
| LTM Mar 2026 | $9.76M | -2.9% | +88.7% | 4.4% | |
| Peer median (excluding LFST) | $113.97M | +8.8% | +23.3% | 3.0% | |
Competitors are the stored peer set for LFST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 667.51M | 859.54M | 1.06B | 1.25B | 1.42B |
| Cost of Revenue | 466M | 622.53M | 753.57M | 848.57M | 963.19M |
| Gross Profit | 201.51M | 237.02M | 302.1M | 402.4M | 461.1M |
| Gross Margin | 30.2% | 27.6% | 28.6% | 32.2% | 32.4% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 433.73M | 377.99M | 410.79M | 363.06M | 382.2M |
| Operating Expenses | 487.86M | 447.19M | 491.23M | 434.01M | 436.95M |
| Depreciation & Amortization | 54.14M | 69.2M | 80.44M | 70.95M | 54.75M |
| EBITDA | (240.06M) | (143.6M) | (104.93M) | 39.87M | 78.78M |
| EBITDA Margin | -36.0% | -16.7% | -9.9% | 3.2% | 5.5% |
| Operating Income | (286.35M) | (210.17M) | (189.13M) | (31.61M) | 24.15M |
| Operating Margin | -42.9% | -24.5% | -17.9% | -2.5% | 1.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 38.91M | 19.93M | 21.22M | 26.54M | 11.66M |
| Other Income / Expenses | (46.75M) | (22.56M) | (17.45M) | (26M) | (11.79M) |
| Income Before Tax | (333.11M) | (232.73M) | (206.58M) | (57.61M) | 12.36M |
| Pre-Tax Margin | -49.9% | -27.1% | -19.6% | -4.6% | 0.9% |
| Income Tax Expense | (25.91M) | (17.17M) | (20.32M) | (170K) | 2.7M |
| Net Income | (307.2M) | (215.56M) | (186.26M) | (57.44M) | 9.66M |
| Net Margin | -46.0% | -25.1% | -17.6% | -4.6% | 0.7% |
| EPS (Basic) | (1.05) | (0.61) | (0.51) | (0.15) | 0.03 |
| EPS (Diluted) | (1.05) | (0.61) | (0.51) | (0.15) | 0.02 |
| Weighted Avg Shares | 327.52M | 355.28M | 367.46M | 379.15M | 386.02M |
| Weighted Avg Shares (Diluted) | 327.52M | 355.28M | 367.46M | 379.15M | 391.14M |
LifeStance Health Group, Inc.
NASDAQ:LFST
Intrinsic Alpha fair value
Locked
Current Price
$13.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.